NCT01946204 2026-04-13
SPARTAN
Aragon Pharmaceuticals, Inc.
Phase 3 Active not recruiting
Clinical Trials
54 trialsNCT02257736 2026-04-13
An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)
Aragon Pharmaceuticals, Inc.
Phase 3 Active not recruiting
NCT02489318 2026-04-13
TITAN
Aragon Pharmaceuticals, Inc.
Phase 3 Active not recruiting
NCT02893917 2026-04-13
Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04108208 2026-04-13
A Study of Apalutamide in Chinese Participants With Non Metastatic Castration Resistant Prostate Cancer (NM-CRPC)
Janssen Research & Development, LLC
Phase 4 Active not recruiting
NCT00859781 2026-04-08
177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With Prostate Cancer
Weill Medical College of Cornell University
Phase 2 Active not recruiting
NCT03419234 2026-04-01
Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel
Eastern Cooperative Oncology Group
Phase 2 Active not recruiting
NCT04530552 2026-04-01
Testing the Effects of Low Dose Apalutamide on Prostate-Specific Antigen (PSA) Levels in Men Scheduled for Removal of the Prostate Gland
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT01251861 2026-03-31
Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT05678322 2026-03-25
Optimizing Timing of rhPSMA-7.3 (18F) for Assessing Site(s) of Recurrent Disease Following Radical Prostatectomy
NYU Langone Health
Phase 3 Active not recruiting
NCT04905082 2026-03-24
HOPE-Genomics Intervention for the Improvement of Cancer Patient Knowledge of Genomics
City of Hope Medical Center
Phase NA Active not recruiting
NCT03787680 2026-03-23
Targeting Resistant Prostate Cancer With ATR and PARP Inhibition (TRAP Trial)
University of Michigan Rogel Cancer Center
Phase 2 Active not recruiting
NCT04689828 2026-03-23
PSMAfore
Novartis
Phase 3 Active not recruiting
NCT03412396 2026-03-19
Apalutamide in Treating Patients With Prostate Cancer Before Radical Prostatectomy
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT03663218 2026-03-18
PREPARE SBRT
Weill Medical College of Cornell University
Phase NA Active not recruiting
NCT03445559 2026-03-17
A Multi-modal, Physician-centered Intervention to Improve Guideline-concordant Prostate Cancer Imaging
VA Office of Research and Development
Phase NA Active not recruiting
NCT03778112 2026-03-09
MRI Guided SBRT for Localized Prostate Cancer
Rush University Medical Center
Phase NA Active not recruiting
NCT03808077 2026-03-09
The Effect of Deep Versus Moderate Muscle Relaxants in Men During and After Robotic Surgery for Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT02522715 2026-02-24
Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer
OHSU Knight Cancer Institute
Phase 1/2 Active not recruiting
NCT03254420 2026-02-20
RCMIGI
Institut du Cancer de Montpellier - Val d'Aurelle
Phase NA Active not recruiting
NCT04751929 2026-02-20
Abemaciclib With or Without Atezolizumab for mCRPC
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT05320406 2026-02-12
REVELUTION
Emory University
Phase 2 Active not recruiting
NCT03796767 2026-01-28
SOAR
University of Utah
Phase 2 Active not recruiting
NCT03246347 2026-01-23
A Trial of Androgen Deprivation, Docetaxel, and Enzalutamide for Metastatic Prostate Cancer
Wake Forest University Health Sciences
Phase 2 Active not recruiting
NCT04647526 2026-01-13
SPLASH
Eli Lilly and Company
Phase 3 Active not recruiting
NCT03809000 2025-12-30
STEEL
RTOG Foundation, Inc.
Phase 2 Active not recruiting
NCT04446117 2025-12-18
CONTACT-02
Exelixis
Phase 3 Active not recruiting
NCT05470699 2025-12-17
RefleXion PET/CT Imaging Performance in Patients With Prostate Cancer
City of Hope Medical Center
Phase NA Active not recruiting
NCT04090528 2025-12-05
pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer
University of Wisconsin, Madison
Phase 2 Active not recruiting
NCT02312557 2025-12-03
Pembrolizumab in Treating Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Enzalutamide
OHSU Knight Cancer Institute
Phase 2 Active not recruiting
NCT05696444 2025-11-25
Medtronic Hugoâ„¢ Robotic Assisted Surgery (RAS) System in Urologic Surgery (Expand URO)
Medtronic - MITG
Phase NA Active not recruiting
NCT03582475 2025-11-12
Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate
Jonsson Comprehensive Cancer Center
Phase 1 Active not recruiting
NCT03218826 2025-10-30
PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT05779943 2025-10-27
Comparison of 18F-rhPSMA-7.3 PET/CT With and Without Furosemide in Biochemical Recurrence of Prostate Cancer
Emory University
Phase 2 Active not recruiting
NCT03217747 2025-10-23
Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies
M.D. Anderson Cancer Center
Phase 1/2 Active not recruiting
NCT03517969 2025-10-20
M6620 and Carboplatin With or Without Docetaxel in Treating Patients With Metastatic Castration-Resistant Prostate Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT03042468 2025-09-17
Phase I Dose-escalation Study of Fractionated 177Lu-PSMA-617 for Progressive Metastatic CRPC
Weill Medical College of Cornell University
Phase 1/2 Active not recruiting
NCT03317990 2025-09-04
NeuroSAFEPROOF
University College, London
Phase NA Active not recruiting
NCT00002540 2025-07-23
Screening for Prostate Cancer in Older Patients (PLCO Screening Trial)
National Cancer Institute (NCI)
Phase NA Active not recruiting
NCT02923180 2025-07-22
Neoadjuvant Enoblituzumab (MGA271) in Men With Localized Intermediate and High-Risk Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Active not recruiting
NCT03834493 2025-07-18
KEYNOTE-641
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT02319837 2025-07-08
Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)
Pfizer
Phase 3 Active not recruiting
NCT05288166 2025-06-27
CYCLONE 3
Eli Lilly and Company
Phase 3 Active not recruiting
NCT03873805 2025-06-26
PSCA-CAR T Cells in Treating Patients With PSCA+ Metastatic Castration Resistant Prostate Cancer
City of Hope Medical Center
Phase 1 Active not recruiting
NCT01342367 2025-06-10
Feasibility of Hormones and Radiation for Intermediate or High Risk Prostate Cancer
University of Chicago
Phase NA Active not recruiting
NCT03725761 2025-05-13
Sacituzumab Govitecan in Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Second Generation AR-Directed Therapy
University of Wisconsin, Madison
Phase 2 Active not recruiting
NCT00567580 2025-05-09
Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer
Radiation Therapy Oncology Group
Phase 3 Active not recruiting
NCT03600350 2025-05-09
pTVG-HP and Nivolumab in Patients With Non-Metastatic PSA-Recurrent Prostate Cancer
University of Wisconsin, Madison
Phase 2 Active not recruiting
NCT03689699 2025-04-29
Nivolumab and BMS-986253 for Hormone-Sensitive Prostate Cancer (MAGIC-8)
Columbia University
Phase 1/2 Active not recruiting
NCT03706365 2025-04-20
CYCLONE 2
Eli Lilly and Company
Phase 2/3 Active not recruiting